All GLG News Analyses Filed Under: Oncology

Exciting data.  Target important and partially validated.  Santarus a competitor with an antisense approach.  Fibrogen Astellas trial of HIF prolyl hydroxylase inhibitor stopped due to a death.     

Essentially we are moving into an arena where cancer drugs will be more and more specific to individual groups of patients with cancer. For example in breast cancer all patients used to be treated the same. Now patients with tumours that are ER positive are given hormonal therapies and not those with...

It shares a common mechanism of action with Wyeth's Torisel (mTOR inhibition) and will at least share the market for recurrence after a TK inhibitor fails.

In the accident of the cancer genome there will always be collateral damage. The difficulty is therefore distinguishing between mutations that are driving cell survival and proliferation versus those which merely are passengers, neutral changes that arose at precisely the same time or as a consequence...

Roche Holding may well be leading the way to make gene analysis more cost effective and individualize cancer care by targeting the mutations!!

Merck's HPV vaccine, Gardasil is expected to be approved for boys to extend "herd immunity" and offer more prevention to girls from cervical cancer. This " altruistic" goal comes with benefits for boys: eradication of 90 % of genital warts cases, and possible long term prevention of anal , penile, and...

As expected, FDA gave accelerated approval for Genetech's Avastin in metastatic breast cancer, thus requiring Genentech to do further studies to show survival benefit and confirm the PFS survival. This decision will "officially" introduces Avastin to breast cancer market, where use has been already...

FDA approval of Avastin in the treatment of advanced breast cancer will have an effect on the sales of the drug, but it is not clear to me how significant that effect will be, since it is already approved in Europe and has been widely used off-label for USA breast cancer patients already. I am glad...

Merck intends to market this viral vaccine to "protect" women from the risk of cervical carcinoma.

Treanda (Bendamustine) combines the activity of a purine analog and alkylating agent, two of the most potent cytotoxic classes in therapy of indolent NHL.  Older data from Europe as well as more recent clinical trials have confirmed the excellent activity of Treanda in indolent NHL and CLL. ...